Login to Your Account

Biosimilars continue their march on RA market, bolstered by bioequivalence studies

By Michael Fitzhugh
Staff Writer

Wednesday, June 10, 2015
New head-to-head data proving biosimilar versions of some of the world's bestselling RA therapies are as safe and effective as their branded counterparts are being presented by Merck & Co. Inc., its partner Samsung Bioepis Co. Ltd. and competitors at the European League Against Rheumatism Annual Congress this week.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription